Cite
APA Citation
Fischer, S., Klenske, E., Schmitt, H., Vitali, F., Hirschmann, S., Koch, F., Ramming, A., Zundler, S., Nagore, D., Uter, W., Neurath, M. F., & Atreya, R. (n.d.). p607 Clinical outcomes and immunogenicity analysis over 6 months following a switch from originator infliximab (Remicade®) to the biosimilar SB2 (Flixabi®) in inflammatory bowel disease patients. Journal of Crohn's and colitis, 12, S416. http://access.bl.uk/ark:/81055/vdc_100095494689.0x00000b